Aripiprazole Long-Acting Intramuscular Injection Augmentation of Sertraline in Obsessive–Compulsive Disorder in Adolescence. A case report
Downloads
Published
How to Cite
Issue
Section
DOI:
https://doi.org/10.31766/revpsij.v37n1a4Keywords:
Obsessive-Compulsive Disorder, Adolescent Psychiatry, Aripiprazole, Drug Synergism, Long-Acting AntipsychoticsAbstract
Obsessive-compulsive disorder is a severe and disabling pathology. First-line treatment does not achieve full remission in almost half of patients. In adults, the efficacy of the adjuvant treatment with aripiprazole has been demonstrated in these cases. There is not enough evidence in the adolescent population, although some promising results have been published. Scant evidence is available on the efficacy and safety of long-acting injectable antipsychotics in adolescents. Their use is recommended only in psychotic disorders with insufficient response due to lack of adherence. However, some authors suggest their use in other pathologies. The case of an adolescent patient with obsessive-compulsive disorder resistant to first-line treatment is presented. The adjuvant use of long-acting injectable aripiprazole allows for good control of the obsessive symptoms and helps prevent future episodes.
Downloads
References
Geller DA, March J. Practice parameter for the assessment and treatment of children and adolescents with obsessivecompulsive disorder. J Am Acad Child Adolesc Psychiatry 2012;51(1): 98–113. https://doi.org/10.1016/j.jaac.2011.09.019.
Brakoulias V, Stockings E. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder. Expert Opin Pharmacother 2019;20(1): 47–53. https://doi.org/10.1080/14656566.2018.1540590.
Masi G, Pfanner C, Millepiedi S BS. Aripiprazole Augmentation in 39 Adolescents With Medicationresistant Obsessive-compulsive Disorder. J Clin Psychopharmacol 2010;30(6): 688–93. https://doi.org/10.1097/jcp.0b013e3181fab7b1.
Akyol Ardic U, Ercan ES, Kutlu A, Yuce D, Ipci M, Inci SB. Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive–Compulsive Disorder in Childhood. Child Psychiatry Hum Dev 2017;48(5): 699–704. https://doi.org/10.1007/s10578-016-0694-8.
Arango C, Baeza I, Bernardo M, Cañas F, de Dios C, Díaz-Marsá M, et al. Antipsicóticos inyectables de liberación prolongada para el tratamiento de la esquizofrenia en España. Rev Psiquiatr y Salud Ment 2018;12(2): 92–105. https://doi.org/10.1016/j.rpsm.2018.03.006.
Grupo de trabajo del CIBERSAM para la elaboración de una guía clínica y terapéutica para primeros episodios psicóticos en la infancia y adolescencia. Guía clínica y terapéutica para primeros episodios psicóticos en la infancia y adolescencia. Informe de consenso de Recomendaciones [Internet]. Centro de Investigación Biomédica en Red - CIBER. 2015 [cited 2018 Dec 8].
Lytle S, McVoy M, Sajatovic M. Long-Acting Injectable Antipsychotics in Children and Adolescents. J Child Adolesc Psychopharmacol 2017;27(1): 2–9. https://doi.org/10.1089/cap.2016.0055.
Pope S, Zaraa SG. Efficacy of Long-Acting Injectable Antipsychotics in Adolescents. J Child Adolesc Psychopharmacol 2016;26(4): 391–394. https://doi.org/10.1089/cap.2015.0091.
American Psychiatric Association. DSM-5 Task Force. Manual diagnóstico y estadístico de los trastornos mentales: DSM-5. Ed. Médica Panamericana; 2018.
Fortea A, Ilzarbe D, Espinosa L, Solerdelcoll M, de Castro C, Oriolo G, et al. Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study. J Child Adolesc Psychopharmacol 2018;28(4): 252–257. https://doi.org/10.1089/cap.2017.0096.
© 2021 AEPNyA Todos los derechos reservados
